These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 14982907)

  • 61. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.
    Conde-Agudelo A; Romero R
    Am J Obstet Gynecol; 2009 Jun; 200(6):595-609. PubMed ID: 19482113
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antenatal magnesium sulfate and outcomes for school-aged children.
    Marret S; Bénichou J
    JAMA; 2015 Jan; 313(3):306. PubMed ID: 25603006
    [No Abstract]   [Full Text] [Related]  

  • 63. The use of intravenous magnesium in non-preeclamptic pregnant women: fetal/neonatal neuroprotection.
    Jacquemyn Y; Zecic A; Van Laere D; Roelens K
    Arch Gynecol Obstet; 2015 May; 291(5):969-75. PubMed ID: 25501980
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Proximity of magnesium exposure to delivery and neonatal outcomes.
    Turitz AL; Too GT; Gyamfi-Bannerman C
    Am J Obstet Gynecol; 2016 Oct; 215(4):508.e1-6. PubMed ID: 27177525
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antenatal magnesium sulfate and outcomes for school-aged children--reply.
    Doyle LW; Anderson PJ; Lee KJ
    JAMA; 2015 Jan; 313(3):306-7. PubMed ID: 25603007
    [No Abstract]   [Full Text] [Related]  

  • 66. Comparison of Cerebral Palsy Severity Between 2 Eras of Antenatal Magnesium Use.
    Stetson BT; Buhimschi CS; Kellert BA; Hay K; Buhimschi IA; Maitre NL
    JAMA Pediatr; 2019 Feb; 173(2):188-190. PubMed ID: 30508016
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: a study using the theoretical domains framework.
    Bain E; Bubner T; Ashwood P; Van Ryswyk E; Simmonds L; Reid S; Middleton P; Crowther CA
    BMC Pregnancy Childbirth; 2015 Aug; 15():176. PubMed ID: 26283623
    [TBL] [Abstract][Full Text] [Related]  

  • 68. MgSO(4) neuroprophylaxis: going from evidence to recommendation.
    Andrews J
    Am J Obstet Gynecol; 2010 Jan; 202(1):e17; author reply e17-8. PubMed ID: 19729139
    [No Abstract]   [Full Text] [Related]  

  • 69. Magnesium for neuroprophylaxis: fact or fiction?
    Cahill AG; Caughey AB
    Am J Obstet Gynecol; 2009 Jun; 200(6):590-4. PubMed ID: 19482112
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antenatal magnesium individual participant data international collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE).
    AMICABLE Group
    Syst Rev; 2012 Mar; 1():21. PubMed ID: 22587882
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fetal pharmacotherapy 3: magnesium sulfate.
    Namouz-Haddad S; Koren G
    J Obstet Gynaecol Can; 2013 Dec; 35(12):1101-1104. PubMed ID: 24405877
    [No Abstract]   [Full Text] [Related]  

  • 72. Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial.
    Vilchez G; Dai J; Lagos M; Sokol RJ
    J Matern Fetal Neonatal Med; 2018 Jan; 31(2):178-183. PubMed ID: 28056569
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Magnesium Sulfate for Neuroprotection.
    Killion MM
    MCN Am J Matern Child Nurs; 2015; 40(6):394. PubMed ID: 26488857
    [No Abstract]   [Full Text] [Related]  

  • 74. [Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth].
    Wolf HT; Henriksen TB; Larsen ML; Pinborg A; Hegaard HK; Brok JS; Huusom LD
    Ugeskr Laeger; 2020 Nov; 182(47):. PubMed ID: 33215580
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of the clinical use of magnesium sulfate for cerebral palsy prevention.
    Gibbins KJ; Browning KR; Lopes VV; Anderson BL; Rouse DJ
    Obstet Gynecol; 2013 Feb; 121(2 Pt 1):235-240. PubMed ID: 23344271
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada.
    De Silva DA; Synnes AR; von Dadelszen P; Lee T; Bone JN; ; Magee LA
    Implement Sci; 2018 Jan; 13(1):8. PubMed ID: 29325592
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adherence to uptake of magnesium sulphate for neuroprotection in preterm births <30 weeks at Christchurch Hospital.
    Pang J
    N Z Med J; 2017 Jul; 130(1458):52-53. PubMed ID: 28694540
    [No Abstract]   [Full Text] [Related]  

  • 78. Preterm labor: approach to decreasing complications of prematurity.
    Locatelli A; Consonni S; Ghidini A
    Obstet Gynecol Clin North Am; 2015 Jun; 42(2):255-74. PubMed ID: 26002165
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth.
    Clark EAS; Weiner SJ; Rouse DJ; Mercer BM; Reddy UM; Iams JD; Wapner RJ; Sorokin Y; Malone FD; O'Sullivan MJ; Peaceman AM; Hankins GDV; Dudley DJ; Caritis SN;
    Am J Perinatol; 2018 Aug; 35(10):1012-1022. PubMed ID: 29510423
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis.
    Cahill AG; Odibo AO; Stout MJ; Grobman WA; Macones GA; Caughey AB
    Am J Obstet Gynecol; 2011 Dec; 205(6):542.e1-7. PubMed ID: 22000669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.